BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ, Beecher C, White H, Turner T, Skoetz N, Estcourt L, Mcquilten ZK, Wood EM, Khoury DS, Davenport MP. Determinants of passive antibody efficacy in SARS-CoV-2 infection.. [DOI: 10.1101/2022.03.21.22272672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Franchini M, Casadevall A, Joyner MJ, Focosi D. WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel) 2023;13. [PMID: 36676084 DOI: 10.3390/life13010134] [Reference Citation Analysis]
2 Koutsakos M, Reynaldi A, Lee WS, Nguyen J, Amarasena T, Taiaroa G, Kinsella P, Liew KC, Tran T, Kent HE, Tan H, Rowntree LC, Nguyen THO, Thomas PG, Kedzierska K, Petersen J, Rossjohn J, Williamson DA, Khoury D, Davenport MP, Kent SJ, Wheatley AK, Juno JA. Rapid recall andde novoT cell responses during SARS-CoV-2 breakthrough infection.. [DOI: 10.1101/2022.12.19.521129] [Reference Citation Analysis]
3 Hooper AT, Somersan-Karakaya S, McCarthy SE, Mylonakis E, Ali S, Mei J, Bhore R, Mahmood A, Geba GP, Dakin P, Weinreich DM, Yancopoulos GD, Herman GA, Hamilton JD; COVID-19 Phase 2/3 Hospitalized Trial Team. Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies. mBio 2022;:e0169922. [PMID: 36255239 DOI: 10.1128/mbio.01699-22] [Reference Citation Analysis]
4 Hooper AT, Somersan-karakaya S, Mccarthy SE, Mylonakis E, Ali S, Mei J, Bhore R, Mahmood A, Geba GP, Dakin P, Weinreich DM, Yancopoulos GD, Herman GA, Hamilton JD, the COVID-19 Phase 2/3 Hospitalized Trial Team. Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies.. [DOI: 10.1101/2022.06.14.22276389] [Reference Citation Analysis]
5 Khoury DS, Schlub TE, Cromer D, Steain M, Fong Y, Gilbert PB, Subbarao K, Triccas JA, Kent SJ, Davenport MP. Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection.. [DOI: 10.1101/2022.06.05.22275943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Callaway E. COVID antibody drugs work best when given as early as possible. Nature 2022. [PMID: 35354978 DOI: 10.1038/d41586-022-00893-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]